Life-Changing, Non-Toxic Cancer Therapy

Dr. leonard’s cancer research fund

Supporting research around a non-toxic, life changing cancer therapy housed at the University of Minnesota, Dr. Leonard’s Cancer Research Fund was founded to carry on the work and mission started by Dr. Arnold Leonard. Today, the lab is led by Dr. Saltzman and a dedicated, efficient lab of five scientists. With significant advancements and Doc’s life’s work coming to fruition, 100% of donated funds go directly to this incredible research.

our research

2023 Cancer Research Lab Update

In the past year we have been working with mice that have tumors induced by exposure to a chemical that causes cancer to develop from single cells, as it does in humans. Using this model will ensure a more successful transfer of our therapy to clinical human trials. READ MORE

ABOUT THE FUND

  • The Arnold S. Leonard Cancer Research Fund operates exclusively to engage in, advance, support, promote, raise money for and administer research and educational activities in genetic engineering to boost the immune system to fight cancer solely through the non-profit corporation, University of Minnesota Foundation.

  • Dr. Leonard attended the University of Minnesota, graduating from the Medical School in 1955 and receiving his Ph.D. in 1963. While in medical school, he worked in the operating room during the first open-heart surgery. After completing residency in General Surgery, he was specifically chosen by Dr. Wangensteen to seek specialty training in Pediatric Surgery.

    He conducted the first thorascopic surgical procedure at the University of Minnesota, breaking into the minimally invasive surgery arena and leading the way to the development of advanced laparoscopic and thoracoscopic techniques. Dr. Leonard has developed several medical devices including a novel long-term central venous access catheter that is the most popular long term central catheter used today in the United States for the delivery of chemotherapeutic agents in cancer patients. He has contributed to the understanding of metastatic Wilm’s tumor and its role of neoadjuvant chemotherapy; a move by the Children’s Cancer Research Committee that has literally saved thousands of lives throughout the world. He also developed a method to expose the spine from an anterior approach; a technique that has revolutionized the treatment of scoliosis. Dr. Leonard also developed a novel method to correct chest deformities; Pectus Excavatum and Pectus Carinatum. To date, he has performed over 1500 of such repairs and is considered to be one of the world’s experts in the treatment of such deformities. Surgical protocols that he developed concerning the treatment of children with cystic fibrosis are now employed nationwide.

    He has given over 60 national and international talks and authored over 260 peer-reviewed publications. Dr. Leonard’s research laboratory has received two American College of Surgeons awards and the Watson Award from the University of Minnesota for innovative approaches in boosting the immune system. He holds an Endowed Chair in Pediatric Surgery in the Department of Surgery at the University of Minnesota and continues to research Genetic Engineering.

    Dr. Leonard continues to raise funds for the Saltzman lab at the University of Minnesota and attends weekly lab meetings with the team of Doctors, Scientists and Volunteers working on this cutting edge cancer research that Dr. Leonard began over 20 years ago. Dr. Leonard continues to enjoy gardening his championship Dahlias, his growing number of great grandchildren, and attending University of Minnesota alumni events.

  • As we learn more about how cancers develop and spread, the bioengineering cancer research lab at the University of Minnesota has focused on the tumor microenvironment where cancers can grow and flourish.

    In addition, the lab uses engineered salmonella to carry proteins that block the cancer’s ability to suppress the immune system.

    Using genetically altered Salmonella to deliver a cocktail of immune modulating proteins right to a cancerous tumor (into the tumor microenvironment), the immune system is stimulated to make cancer killing immune cells.

    Thus, they are altering the cancer’s microenvironment by simultaneously stimulating the immune system to kill cancer and STOP the cancer cell’s ability to spread and grow.

    The FDA will require several studies once the lab determines which combination is most effective for the Investigational New Drug (IND) application.

    Funds are currently being used to study a variety of cancer types.

THE LAB

Our research lab is going against the system, trying something that is different than the current cancer treatment that is available; something without the damaging side effects that traditional treatments currently produce.

Now led by Dr. Saltzman, the cancer research lab is nearing the goal of identifying the best “bug” to take to the FDA for application for Human Phase 2 clinical trials.

Phase 1 was successfully completed several years ago, and the next generation cancer therapy model that the lab is working on now will be presented to the FDA soon, and is expected to be curative.

Our therapy model in the research lab is measuring as effective as 100% chemotherapy treatment, when used in conjunction with a lower dose of chemotherapy in mice models. 25% of chemotherapy combined with our cancer therapy has the same cancer killing effect as 100% chemotherapy in the lab model in mice, without side effects typically associated with the toxic chemotherapy treatment drugs that are available now.

Another unique aspect of our cancer work is that we are using an autochronus model that specifically mimics the human response to cancer, as opposed to the mouse model that most other research is based on. This sets us apart from other cancer research models.

Also interesting to note, 92% of FDA clinical trials fail. While using the autochronus model is a harder path to results, getting this hard work done up front, taking the time to do it this way - before bringing it to the FDA - ensures a significantly higher chance of being accepted for clinicial trial, and the best shot at reaching the curative objective that is the goal.

Once we are confident with the very best “bug”, and when we can get this to the FDA, we are there.

Our Board of

Directors


Dr. Arnold S. Leonard

M.D., Ph.D. | Chairman

Dr. Leonard continues to attend weekly lab meetings and keeps up on the developments in the lab this way, making sure things stay focused and personnel are taken care of. He continues to be responsible for raising the majority of funds necessary to keep the lab running each year. 

Trustees


Dr. Arnold S. Leonard, Chairman

Phil Kalleberg, Vice Chairman

Dr. Robert Acton, Trustee

Brittany Woitas, Trustee

Dave Libert, Trustee

Bill Gorrilla, Trustee

Zach Meyer, Trustee

Trina Jacobson, Trustee

Dan Kolpin, Trustee

Dave Brockpahler, Trustee